AdCLD-CoV19

AdCLD-CoV19
Vaccine description
Target	SARS-CoV-2
Vaccine type	Viral vector
Clinical data
Routes of; administration	Intramuscular

Last updated February 29, 2024

AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co,^[1]^[2] a company from South Korea.^[3]

A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea.^[4] In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.^[5] Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022.^[6] In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.^[7]

Related Research Articles

H5N1 clinical trials are clinical trials concerning H5N1 vaccines, which are intended to provide immunization to influenza A virus subtype H5N1. They are intended to discover pharmacological effects and identify any adverse reactions the vaccines may achieve in humans.

ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.

<span class="mw-page-title-main">COVIran Barekat</span> COVIran Barakat vaccine against COVID-19

COVIran Barekat is a COVID-19 vaccine developed in Iran by Shifa Pharmed Industrial Group, a subsidiary of the Barkat Pharmaceutical Group. It is an inactivated virus-based vaccine. Iranian authorities have authorized its emergency use. This makes it the first locally developed COVID-19 vaccine to be approved for emergency use in the Middle East.

The CureVac COVID-19 vaccine was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). The vaccine showed inadequate results in its Phase III trials with only 47% efficacy. In October 2021 CureVac abandoned further development and production plans for CVnCoV and refocused efforts on a cooperation with GlaxoSmithKline.

ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council. It is approved for emergency use in India.

Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine.

iNCOVACC is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, American company Precision Virologics and the Washington University School of Medicine in St Louis, Missouri, United States.

The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases. The other inactivated virus COVID-19 vaccine developed by Sinopharm is the BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.

The MVC COVID-19 vaccine, designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine, is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company Dynavax Technologies, and the U.S. National Institutes of Health.

AWcorna, originally termed ARCoV and also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science. In contrast to other mRNA COVID vaccines, such as those by Pfizer-BioNtech and Moderna, this vaccine primarily targets the Sars-CoV-2 receptor-binding domain of the spike protein, rather than the entire spike protein. It is approved for Phase III trials in China, Mexico, Indonesia, and Nepal.

NDV-HXP-S is a COVID-19 vaccine candidate developed under the leadership of Peter Palese, Adolfo García-Sastre, and Florian Krammer at the Icahn School of Medicine at Mount Sinai.

EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.

V-01 is a protein subunit COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc.

GX-19 is a COVID-19 vaccine candidate developed by Genexine consortium.

mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.

FAKHRAVAC is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials. It is currently in phase III. It received emergency use authorization in Iran on 9 September 2021.

COVAX-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, in collaboration with CinnaGen, a private company with operations in the Middle East. It is under clinical trial in collaboration with the Iranian company CinnaGen.

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:

Noora is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in collaboration with Plasma Darman Sarv Sepid Co. in Iran.

S-268019-b is a protein subunit COVID-19 vaccine candidate developed by Shionogi.

References

↑ Chan-Hyuk K (10 December 2020). "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review . Retrieved 22 August 2021.
↑ Chan-hyuk K (11 August 2021). "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review . Retrieved 22 August 2021.
↑ "Cellid Co Ltd, Company Profile and News". Bloomberg Markets.
↑ Clinical trial number NCT04666012 for "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers" at ClinicalTrials.gov
↑ Cellid Co (21 January 2022). "A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.
↑ Shin SP, Shin KS, Lee JM, Jung IK, Koo J, Lee SW, et al. (April 2022). "The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates". Vaccines. 10 (5): 712. doi: 10.3390/vaccines10050712 . PMC 9147121 . PMID 35632468.
↑ Cellid Co (27 August 2022). "A Phase IIb, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults Aged 19 Years Old and Above". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.

Scholia has a profile for AdCLD-CoV19 (Q108415181).

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Chan-Hyuk K (10 December 2020). "LG Chem pushes for Covid-19 vaccine CMO deal". Korea Biomedical Review . Retrieved 22 August 2021.

[2] Chan-hyuk K (11 August 2021). "Covid-19 vaccine trials stalled by rare chance to get licensed vaccines". Korea Biomedical Review . Retrieved 22 August 2021.

[3] "Cellid Co Ltd, Company Profile and News". Bloomberg Markets.

[Trial_registration_NCT04666012-4] Clinical trial number NCT04666012 for "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers" at ClinicalTrials.gov

[Trial_registration_NCT05047692-5] Cellid Co (21 January 2022). "A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.

[Preclinical_2022-6] Shin SP, Shin KS, Lee JM, Jung IK, Koo J, Lee SW, et al. (April 2022). "The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates". Vaccines. 10 (5): 712. doi: 10.3390/vaccines10050712 . PMC 9147121 . PMID 35632468.

[Registration_phase_2_trial_NCT05520970-7] Cellid Co (27 August 2022). "A Phase IIb, Multicenter, Observer-Blinded, Randomized, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of the AdCLD-CoV19-1 in Healthy Adults Aged 19 Years Old and Above". clinicaltrials.gov. National Institutes of Health. Retrieved 27 September 2022.

[1]

[2]

[3]

[4]

[5]

[6]

[7]